India Outperformance Overshadowed by PAT Collapse

Alkem delivered solid revenue growth and hit its India market-outperformance target in Q1 FY-2027. But the quarter's real story lies in a paradox: EBITDA margin held flat at 20.5%, yet reported profit collapsed 22%. The gap is structural, not operational — and it defines near-term risk.

Reported PAT of ₹521 crore would look fine if not for two headwinds. First, the consolidated tax rate spiked to 30–32%, up from a prior stand-alone 27–28%. Why? Because new ventures — the US-based CDMO (Enzene) and MedTech assets — are reporting losses, and management is not recognizing deferred tax assets on those entities. Second, the CDMO is burning ₹60 crore per quarter with zero revenue yet (operational since November 2025). This structural drag is why core-business EBITDA margin sat flat while profit tanked. Strip out the new-venture losses and the tax-rate hit, and core pharma's underlying profitability is consistent.

The US guidance softened. Prior calls promised 'high single-digit' growth; this time management revised to 'high single-digit to mid', citing volume weakness and Daman OAI headwinds (though they claim no FY-2027 impact). Occlutech (MedTech, acquired mid-July) saw its margin timeline extended: original guidance of ~10% margins 'in the near term' has now become 7–8% EBITDA improvement 'over 3–4 years', a realistic reset but a downgrade in tone. India guidance held steady — 100 bps outperformance remains on track, with branded generics +12% and Trade Generics flattish by design (DSO discipline for ROCE). The CDMO breakeven target is FY-2028 at USD 25–30 million annualized, not earlier.

The stock is oversold near-term. At ₹5,400, it sits below its 20-day, 50-day, and 200-day moving averages (₹5,571, ₹5,537, ₹5,544), and the RSI of 28.6 signals oversold conditions. The stock is 8.99% below its all-time high and 6.4% above its 52-week low — so downside from fundamental weakness is limited, but upside is not yet priced in. The post-result price reaction was muted: day 1 saw a +0.11% move, and by day 3 the gain had settled to +0.27%. This lack of enthusiasm suggests the market is taking a wait-and-see stance on Daman OAI resolution and new-venture execution.

Institutional positioning is mixed. Domestic institutions (DII) are adding gently (up 1.23 percentage points quarter-on-quarter to 22.63%), and mutual funds are visible in block deals at ₹5,200 — suggesting some tactically astute buyers are opportunistic on oversold levels. But foreign institutions (FII) are flat (10.42%, up just 0.26pp), which usually signals hesitation on emerging-market pharma amid macro uncertainty. Promoters have trimmed 1.5 percentage points to 49.70%, and insider block sales are visible at ₹5,200, a mild negative signal. Taken together: the market is not panicking, but it's not excited either. Valuation is attractive near-term, but conviction will return only when Daman is resolved and CDMO shows material revenue.